PL2733493T3 - Sposób prognozowania in vitro progresji nowotworu i rezultatu u pacjenta oraz środki do przeprowadzenia wymienionego sposobu - Google Patents

Sposób prognozowania in vitro progresji nowotworu i rezultatu u pacjenta oraz środki do przeprowadzenia wymienionego sposobu

Info

Publication number
PL2733493T3
PL2733493T3 PL14154679.6T PL14154679T PL2733493T3 PL 2733493 T3 PL2733493 T3 PL 2733493T3 PL 14154679 T PL14154679 T PL 14154679T PL 2733493 T3 PL2733493 T3 PL 2733493T3
Authority
PL
Poland
Prior art keywords
prognosis
cancer
patient
outcome
progression
Prior art date
Application number
PL14154679.6T
Other languages
English (en)
Inventor
Jérôme Galon
Franck Pages
Wolf-Herman Fridman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36129834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2733493(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PL2733493T3 publication Critical patent/PL2733493T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
PL14154679.6T 2005-10-19 2006-09-28 Sposób prognozowania in vitro progresji nowotworu i rezultatu u pacjenta oraz środki do przeprowadzenia wymienionego sposobu PL2733493T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05292200A EP1777523A1 (en) 2005-10-19 2005-10-19 An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US76435606P 2006-02-02 2006-02-02

Publications (1)

Publication Number Publication Date
PL2733493T3 true PL2733493T3 (pl) 2016-12-30

Family

ID=36129834

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14154679.6T PL2733493T3 (pl) 2005-10-19 2006-09-28 Sposób prognozowania in vitro progresji nowotworu i rezultatu u pacjenta oraz środki do przeprowadzenia wymienionego sposobu

Country Status (8)

Country Link
US (5) US8481271B2 (pl)
EP (14) EP1777523A1 (pl)
JP (3) JP5256038B2 (pl)
AT (1) ATE523786T1 (pl)
DK (2) DK2733493T3 (pl)
ES (12) ES2374783T3 (pl)
PL (1) PL2733493T3 (pl)
WO (1) WO2007045996A1 (pl)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
US20120135415A1 (en) * 2002-11-15 2012-05-31 Morehouse School Of Medicine Detecting cancer with anti-cxcl13 and anti-cxcr5 antibodies
US20120064089A1 (en) * 2002-11-15 2012-03-15 Morehouse School Of Medicine Anti-cxcl16 and anti-cxcr6 antibodies for the prevention and treatment of cancer and cancer cell migration
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP2392672A1 (en) * 2006-06-02 2011-12-07 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the CD52 gene
WO2008009028A2 (en) * 2006-07-14 2008-01-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods of determining the prognosis of an adenocarcinoma
WO2008076321A1 (en) 2006-12-14 2008-06-26 Schering Corporation Engineered anti-tslp antibody
CN101971033A (zh) * 2007-06-04 2011-02-09 戴诺普雷克斯公司 用于结直肠癌的生物标志物组合
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
GB0723179D0 (en) * 2007-11-27 2008-01-02 Immunovia Ab Diagnostic methods and arrays for use in the same
WO2009120800A2 (en) * 2008-03-25 2009-10-01 University Of Southern California Prognostic panel for urinary bladder cancer
SG189774A1 (en) * 2008-04-10 2013-05-31 Genenews Corp Method and apparatus for determining a probability of colorectal cancer in a subject
US20110117578A1 (en) * 2008-05-29 2011-05-19 Bruce Acres Biomarker for selecting patients and related methods
JP5568807B2 (ja) * 2008-06-06 2014-08-13 静岡県 プロテオミクス解析を用いたメラノーママーカーの同定
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
US8802384B2 (en) * 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
EP2419533A4 (en) * 2009-04-16 2014-12-31 Nat Res Council Canada METHOD FOR DETECTING TUMOR CHARACTER STIKA AND MARKER SETS, TUMOR CLASSIFICATION AND MARKER SETS FOR CANCER
AU2010292532A1 (en) * 2009-08-25 2012-04-05 Berg Llc Methods for treatment of a sarcoma using an epimetabolic shifter (Coenzyme Q10)
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
NZ599761A (en) 2009-11-04 2014-04-30 Merck Sharp & Dohme Engineered anti-tslp antibody
US20120156701A1 (en) * 2009-12-20 2012-06-21 Joseph Anderberg Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102725636B (zh) 2009-12-20 2015-04-01 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
NZ705645A (en) 2010-01-11 2016-05-27 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
AU2015202116B2 (en) * 2010-01-11 2017-06-08 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
AU2011207253B2 (en) 2010-01-20 2015-02-12 Merck Sharp & Dohme Corp. Anti-ILT5 antibodies and ILT5-binding antibody fragments
CA2787755A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
US9404926B2 (en) * 2010-01-29 2016-08-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Immune gene signatures in cancer
GB201009798D0 (en) 2010-06-11 2010-07-21 Immunovia Ab Method,array and use thereof
CN104777313B (zh) 2010-07-09 2017-09-26 私募蛋白质体公司 肺癌生物标记及其用途
WO2012021795A2 (en) 2010-08-13 2012-02-16 Somalogic, Inc. Pancreatic cancer biomarkers and uses thereof
FR2964744B1 (fr) * 2010-09-10 2015-04-03 Univ Versailles St Quentin En Yvelines Test pronostic de l'evolution d'une tumeur solide par analyse d'images
CA2811015A1 (en) 2010-09-15 2012-03-22 Almac Diagnostics Limited Molecular diagnostic test for cancer
JP5784294B2 (ja) * 2010-09-22 2015-09-24 シスメックス株式会社 細胞分析装置および細胞分析方法
DK2619576T3 (da) 2010-09-24 2020-09-07 Niels Grabe Midler og fremgangsmåder til forudsigelse af behandlingsrespons hos en cancerpatient
CA2814150A1 (en) * 2010-10-08 2012-04-12 Epiontis Gmbh Method for determining cancer patient survival based on analyzing tumor-infiltrating overall t-lymphocytes
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
US9593377B2 (en) 2010-12-02 2017-03-14 Dana-Farber Cancer Institute, Inc. Signatures and determinants associated with cancer and methods of use thereof
EP2652508B1 (en) * 2010-12-14 2018-02-07 Jyant Technologies, Inc. The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer
US20140018255A1 (en) * 2011-01-11 2014-01-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for predicting the outcome of a cancer in a patient by analysing gene expression
CN103857421B (zh) * 2011-06-13 2017-09-22 Tla指标免疫疗法公司 治疗癌症的方法和在其中使用的结合试剂
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
US9115388B2 (en) 2011-11-01 2015-08-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gene signature for the prediction of NF-kappaB activity
JP2014533100A (ja) * 2011-11-04 2014-12-11 オスロ ウニヴェルスィテーツスィーケフース ハーエフＯｓｌｏ Ｕｎｉｖｅｒｓｉｔｅｔｓｓｙｋｅｈｕｓ Ｈｆ 結腸直腸癌の分析のための方法およびバイオマーカー
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
ES2707285T3 (es) * 2012-01-20 2019-04-03 Inst Nat Sante Rech Med Método para el pronóstico del tiempo de supervivencia de un paciente que padece un cáncer sólido
JP5970560B2 (ja) * 2012-01-20 2016-08-17 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｂ細胞の密度に基づいて、固形癌に苦しむ患者の生存時間を予測するための方法
US20130203614A1 (en) 2012-02-08 2013-08-08 Jerome Galon Methods for predicting the survival time of a patient suffering from a solid cancer
ES2902879T3 (es) * 2012-06-14 2022-03-30 Inst Nat Sante Rech Med Método de cuantificación de células inmunitarias en tejidos tumorales y sus aplicaciones
EP2872646B1 (en) * 2012-07-12 2017-08-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
CN102854322A (zh) * 2012-07-31 2013-01-02 吴克 一种vefg受体酶联诊断试剂盒及其制备方法
EP2880180B1 (en) * 2012-08-06 2018-10-03 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and kits for screening patients with a cancer
SG11201501413YA (en) 2012-08-31 2015-03-30 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
RU2015121366A (ru) * 2012-11-05 2016-12-27 Новидженикс Са Комбинации биомаркеров для колоректальных опухолей
KR102174578B1 (ko) * 2012-11-27 2020-11-06 폰티피씨아 유니베르시다드 까똘리까 데 칠레 갑상선 종양을 진단하기 위한 조성물 및 방법
WO2014093623A1 (en) * 2012-12-12 2014-06-19 University Of Washington Through Its Center For Commercialization Method and assays for cancer prognosis using jak2
HUE058790T2 (hu) 2012-12-17 2022-09-28 Pf Argentum Ip Holdings Llc CD47+ beteg sejtek kezelése SIRP-alfa-Fc fúziókkal
EP2946211B1 (en) 2013-01-17 2018-02-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2014140896A2 (es) 2013-03-15 2014-09-18 Fundacio Privada Institut De Recerca Biomedica Metodo para el diagnostico, pronostico y tratamiento de la metastasis de un cancer
CN105209919B (zh) * 2013-03-15 2019-03-05 豪夫迈·罗氏有限公司 治疗pd-1和pd-l1相关疾患的生物标志物和方法
KR101672531B1 (ko) * 2013-04-18 2016-11-17 주식회사 젠큐릭스 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도
SG10201709537PA (en) * 2013-05-30 2017-12-28 Genomic Health Inc Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
EP3022561B1 (en) * 2013-07-15 2019-08-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for the prognosis of survival time of a patient suffering from a solid cancer
CN105829885B (zh) * 2013-10-17 2020-08-18 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
EP3091999B1 (en) 2014-01-09 2021-10-20 Hadasit Medical Research Services and Development Ltd. Improved cell compositions and methods for cancer therapy
ES2701092T5 (es) 2014-02-24 2022-05-12 Ventana Med Syst Inc Procedimientos, kits y sistemas para puntuar la respuesta inmunitaria al cáncer por detección simultánea de CD3, CD8, CD20 y FOXP3
CN106661614A (zh) * 2014-03-11 2017-05-10 昆士兰医学研究所理事会 确定癌症侵袭性、预后和治疗响应
WO2015157623A1 (en) * 2014-04-11 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Immune gene signatures in urothelial carcinoma (uc)
ES2916923T3 (es) 2014-07-11 2022-07-06 Ventana Med Syst Inc Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos
WO2016073760A1 (en) * 2014-11-05 2016-05-12 The Regents Of The University Of California Methods for stratifying non-responders to therapies that block pd1/pdl1 axis
BR112017012515A2 (pt) 2014-12-11 2018-01-02 Inbiomotion S.L. membros vinculantes para c-maf humano
EP3073268A1 (en) * 2015-03-27 2016-09-28 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Biomarker panel for diagnosing cancer
WO2016181912A1 (ja) * 2015-05-08 2016-11-17 学校法人 川崎学園 免疫因子を指標とした肺腺癌の予後演算式作成方法と予後推定方法
JP6932365B2 (ja) * 2015-05-14 2021-09-08 公立大学法人大阪 スキルス性胃癌の治療剤、及び胃癌の予後の予測方法
EP3304041B1 (en) 2015-05-26 2021-03-10 IncellDx, Inc. Methods of assessing cellular breast samples and compositions for use in practicing the same
WO2017024019A1 (en) * 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
ES2699322T3 (es) * 2015-08-10 2019-02-08 Univ Medical Hospital China Procedimiento de evaluación de un paciente que padece glioblastoma aplicable a un tratamiento de inmunoterapia a base de vacunas tumorales de células dendríticas
AU2016342269A1 (en) * 2015-10-22 2018-03-29 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
RU2605310C1 (ru) * 2015-12-01 2016-12-20 Федеральное государственное бюджетное учреждение науки Институт физиологии природных адаптаций Уральского отделения Российской академии наук Способ диагностики риска формирования дефицита противоопухолевой иммунной защиты
JP6793746B2 (ja) 2015-12-04 2020-12-02 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 免疫療法有効性の臨床的相関物
JP6443581B2 (ja) * 2016-02-19 2018-12-26 コニカミノルタ株式会社 がんまたは免疫系が関係する疾患の診断または治療のための情報取得方法
CN105911292B (zh) * 2016-05-19 2018-06-26 深圳市衍生生物科技有限公司 用于组合分析CD11c+CD11b+ DC亚群以及其分化程度和功能的试剂盒及方法
JP2019523889A (ja) 2016-06-06 2019-08-29 アスチュート メディカル，インコーポレイテッド インスリン様増殖因子結合タンパク質７およびメタロプロテアーゼ２の組織阻害剤を使用する急性腎臓傷害の管理
US9990713B2 (en) * 2016-06-09 2018-06-05 Definiens Ag Detecting and visualizing correlations between measured correlation values and correlation reference values of a pathway
WO2018039490A1 (en) 2016-08-24 2018-03-01 Genomedx Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US20190256603A1 (en) * 2016-11-11 2019-08-22 Medimmune, Llc Anti-pd-l1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
JP7235508B2 (ja) * 2016-11-24 2023-03-08 第一三共株式会社 Ｐｄ－１免疫チェックポイント阻害剤による治療に対するがんの感受性を予測する方法
EP3580349A1 (en) * 2017-02-07 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Tim-3 for assessing the severity of cancer
EP3593140A4 (en) 2017-03-09 2021-01-06 Decipher Biosciences, Inc. SUBTYPING PROSTATE CANCER TO PREDICT RESPONSE TO HORMONE THERAPY
CA3065304A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
WO2018222718A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
CN111201438A (zh) 2017-06-02 2020-05-26 朱诺治疗学股份有限公司 与和细胞疗法相关的毒性有关的制品和方法
JP7024957B2 (ja) * 2017-07-04 2022-02-24 株式会社Ｄｎａチップ研究所 大腸癌の異時性転移の有無を予測する方法およびそれに用いるキット
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
WO2019020556A1 (en) 2017-07-24 2019-01-31 Ventana Medical Systems, Inc. METHODS AND SYSTEMS FOR ASSESSING INFILTRAT OF IMMUNE CELLS IN TUMOR SAMPLES
AU2018310987A1 (en) * 2017-08-04 2020-02-27 Decipher Biosciences, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
AU2018316343A1 (en) 2017-08-11 2020-02-13 Genentech, Inc. Anti-CD8 antibodies and uses thereof
US20210132042A1 (en) * 2017-11-01 2021-05-06 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
WO2019108135A1 (en) 2017-11-30 2019-06-06 Singapore Health Services Pte. Ltd. A system and method for classifying cancer patients into appropriate cancer treatment groups and compounds for treating the patient
GB201801067D0 (en) 2018-01-23 2018-03-07 Price Nicola Kaye Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof
DK3746790T3 (da) 2018-01-31 2023-12-11 Ventana Med Syst Inc Fremgangsmåder og systemer til evaluering af immuncelleinfiltrat i kolorektal stadie III cancer
EP3752252A4 (en) 2018-02-12 2021-11-17 Hadasit Medical Research Services and Development Ltd. MODULATION OF SLAMF6 SPLICE VARIANTS FOR CANCER THERAPY
WO2019164870A1 (en) * 2018-02-20 2019-08-29 Medimmune, Llc Expression of signature mrnas for identifying patients responsive to anti-pd-l1 antibody therapy
BR112020017715A2 (pt) 2018-03-16 2020-12-29 Zoetis Services Llc Vacinas de peptídeo contra interleucina-31
WO2019234221A1 (en) * 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
CN108949982B (zh) * 2018-07-09 2021-10-26 中国医科大学附属第一医院 一种利用免疫共刺激分子评价胶质瘤临床预后的方法
EP3820520A4 (en) * 2018-07-12 2022-05-11 Corvus Pharmaceuticals, Inc. METHODS FOR DETECTING AND TREATING CANCERS HAVING ACTIVATION OF THE ADENOSINE PATHWAY
US20210381058A1 (en) * 2018-10-01 2021-12-09 Nantomics, Llc Evidence based selection of patients for clinical trials using histopathology
KR102198404B1 (ko) * 2019-04-15 2021-01-05 고려대학교 산학협력단 대장암에서 항암제 내성과 관련된 cd133 및 이의 용도
WO2020256868A1 (en) * 2019-05-16 2020-12-24 Trustees Of Boston University Immune system modulators for the treatment of squamous lung premalignancy
US20220326243A1 (en) * 2019-05-21 2022-10-13 Acurasysbio Co., Ltd. Composition for cancer diagnosis
JP2022536075A (ja) 2019-06-03 2022-08-12 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 処置レジメンを調節する方法
CN110488015A (zh) * 2019-08-27 2019-11-22 成都和同易创生物科技有限公司 趋化因子cxcl14在预测结肠癌预后中的应用
TW202132573A (zh) 2019-11-07 2021-09-01 美商昂克賽納醫療公司 腫瘤微環境之分類
CN110895280B (zh) * 2019-12-03 2022-11-18 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于预测鼻咽癌转移的免疫评分及其应用
US11725048B2 (en) 2019-12-20 2023-08-15 Hudson Institute of Medical Research CXCL10 binding proteins and compositions thereof
JP2023517183A (ja) * 2020-03-06 2023-04-24 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション がんを治療するためのｉｒｆモジュレーター発現腫瘍溶解性ウィルス
CN111458509B (zh) * 2020-04-14 2023-09-22 中国人民解放军海军军医大学第三附属医院 肝细胞癌预后评估的生物标志物及其试剂盒和方法
EP4172628A1 (en) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
JP2023531305A (ja) 2020-06-30 2023-07-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術前補助療法後の固形癌患者の再発及び／又は死亡のリスクを予測するための方法。
CN111638342A (zh) * 2020-07-08 2020-09-08 上海市浦东新区公利医院(第二军医大学附属公利医院) Sox17蛋白在制备肾透明细胞癌诊断或预后评估试剂盒中的应用
CN112365951B (zh) * 2020-11-24 2024-03-08 竹安（北京）生物科技发展有限公司 一种基于免疫检测的肿瘤用药指导系统及方法
CN112489800A (zh) * 2020-12-03 2021-03-12 安徽医科大学第一附属医院 一种前列腺癌患者的预后评估系统及其应用
KR102427057B1 (ko) * 2020-12-04 2022-07-29 전남대학교산학협력단 단일섬유종양/혈관주위세포종 전이 진단 또는 예후 분석용 바이오 마커 및 이를 이용한 진단방법
EP4026918A1 (en) * 2021-01-12 2022-07-13 Koninklijke Philips N.V. Prediction of an outcome of a colorectal cancer subject
EP4321625A1 (en) * 2021-04-06 2024-02-14 Industry Foundation of Chonnam National University Method for predicting prognosis and responsiveness to anticancer therapy of cancer patients
CN113834889B (zh) * 2021-09-29 2024-02-13 中国医学科学院北京协和医院 垂体柄阻断综合征生物标志物及其确定方法和应用
WO2023076701A2 (en) * 2021-10-29 2023-05-04 La Jolla Institute For Immunology Methods for modulating an immune response to cancer or tumor celts
CN114019163A (zh) * 2021-11-02 2022-02-08 复旦大学附属中山医院 基于活化b细胞表达的结肠癌预后诊断用标记物及其用途
CN113834941B (zh) * 2021-11-02 2024-01-05 复旦大学附属中山医院 基于b细胞表达的结肠癌预后诊断用标记物及其用途
WO2023175366A1 (en) 2022-03-17 2023-09-21 Veracyte Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer
CN114657252A (zh) * 2022-04-26 2022-06-24 复旦大学 一种用于脑恶性胶质瘤诊断和预后的趋化因子及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
CA2087413A1 (en) 1992-01-17 1993-07-18 Joseph R. Lakowicz Fluorescent energy transfer immunoassay
US5556763A (en) * 1992-04-06 1996-09-17 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Evaluation and treatment of patients with progressive immunosuppression
DE69426948T2 (de) * 1993-02-09 2001-10-11 Becton Dickinson Co Automatische Bestimmung der Zellinie schwerer Leukämien durch Flusszytometrie
US5658744A (en) * 1994-07-22 1997-08-19 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying patients having an altered immune status
AU4977896A (en) * 1995-02-17 1996-09-04 Immunotherapy, Inc. Immunotherapy screening, prognosis, and treatment methods and compositions
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6892141B1 (en) 2000-03-17 2005-05-10 Hitachi, Ltd. Primer design system
US6656683B1 (en) * 2000-07-05 2003-12-02 Board Of Regents, The University Of Texas System Laser scanning cytology with digital image capture
AU2002308216A1 (en) * 2001-02-26 2002-09-12 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas
FR2821605B1 (fr) * 2001-03-01 2003-05-30 Eads Airbus Sa Procede et dispositif pour accelerer la destruction d'au moins deux vortex dans le sillage d'un mobile, en particulier d'un avion
AR036993A1 (es) * 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
EP1399460A4 (en) * 2001-04-27 2005-04-13 Sunnybrook & Women S College H GENESIS ASSOCIATED WITH BREAST CANCER AND THEIR USE
CA2468713A1 (en) 2001-11-30 2003-06-12 University Of Rochester Multiplex real-time quantitative pcr
AU2003206443A1 (en) 2002-02-20 2003-09-09 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Hedgehog-related prophylaxis, therapy and diagnosis of gi tract carcinogenesis
EP3287144A1 (en) * 2002-07-03 2018-02-28 ONO Pharmaceutical Co., Ltd. Immunopotentiating compositions
ATE407691T1 (de) * 2003-07-18 2008-09-15 Schering Corp Behandlung und diagnose von neoplasien mit tslp (thymic stromal lymphopoietin)
PT1810026T (pt) * 2004-10-06 2018-06-11 Mayo Found Medical Education & Res B7-h1 e pd-1 no tratamento do carcinona de células renais

Also Published As

Publication number Publication date
WO2007045996A1 (en) 2007-04-26
US20190178892A1 (en) 2019-06-13
EP2420837B1 (en) 2014-03-05
EP3364191A1 (en) 2018-08-22
EP2420838B1 (en) 2014-04-16
EP2420835B1 (en) 2014-03-05
EP3088894A1 (en) 2016-11-02
ES2469102T3 (es) 2014-06-17
ES2785033T3 (es) 2020-10-05
ES2374783T3 (es) 2012-02-22
EP2420840B1 (en) 2015-11-11
EP2420841A3 (en) 2012-09-26
EP2420839A3 (en) 2012-09-19
EP2420837A3 (en) 2012-05-30
US8481271B2 (en) 2013-07-09
EP2733493A1 (en) 2014-05-21
EP2420840A3 (en) 2012-08-08
EP2420841A2 (en) 2012-02-22
US20220308063A1 (en) 2022-09-29
EP2420836A3 (en) 2012-05-30
JP2012154944A (ja) 2012-08-16
EP2420836A2 (en) 2012-02-22
JP2014158500A (ja) 2014-09-04
EP2241891B1 (en) 2012-10-31
EP2733493B1 (en) 2016-06-22
EP2420839B1 (en) 2014-04-16
JP5921602B2 (ja) 2016-05-24
ES2561527T3 (es) 2016-02-26
ES2674560T3 (es) 2018-07-02
US20140057257A1 (en) 2014-02-27
DK2420840T3 (en) 2016-02-08
EP2420840A2 (en) 2012-02-22
ES2470165T3 (es) 2014-06-23
EP2420839A2 (en) 2012-02-22
EP2420836B1 (en) 2014-03-05
ATE523786T1 (de) 2011-09-15
EP2420838A3 (en) 2012-09-26
EP2420835A2 (en) 2012-02-22
ES2469103T3 (es) 2014-06-17
EP3088894B1 (en) 2018-03-28
JP5789216B2 (ja) 2015-10-07
EP3364191B1 (en) 2020-03-18
EP3715849A1 (en) 2020-09-30
ES2398907T3 (es) 2013-03-22
US11300569B2 (en) 2022-04-12
ES2480691T3 (es) 2014-07-28
EP1943520B1 (en) 2011-09-07
ES2531659T3 (es) 2015-03-18
EP3715849B1 (en) 2023-08-09
ES2480690T3 (es) 2014-07-28
EP2420838A2 (en) 2012-02-22
DK2733493T3 (en) 2016-09-19
EP2420835A3 (en) 2012-05-30
US20090215053A1 (en) 2009-08-27
EP2420841B1 (en) 2014-12-03
US10191059B2 (en) 2019-01-29
EP2420837A2 (en) 2012-02-22
ES2592169T3 (es) 2016-11-28
JP2009515148A (ja) 2009-04-09
EP1777523A1 (en) 2007-04-25
JP5256038B2 (ja) 2013-08-07
EP2241891A1 (en) 2010-10-20
US20150268245A1 (en) 2015-09-24
EP1943520A1 (en) 2008-07-16

Similar Documents

Publication Publication Date Title
PL2733493T3 (pl) Sposób prognozowania in vitro progresji nowotworu i rezultatu u pacjenta oraz środki do przeprowadzenia wymienionego sposobu
EP2392678A3 (en) Prognosis prediction for colorectal cancer
HK1148783A1 (zh) 用於乳房腺的預後的基因表達標記
WO2007095644A3 (en) Reagents and methods for cancer prognosis and pathological staging
WO2005039382A3 (en) Prediction of likelihood of cancer recurrence
WO2007109236A8 (en) Microrna fingerprints during human megakaryocytopoiesis
MX2009013410A (es) Biomarcadores para predecir capacidad de respuesta anti-tnf o sin capacidad de respuesta.
WO2005020785A3 (en) Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2011046964A3 (en) Inhibitors of bruton's tyrosine kinase
WO2007114947A3 (en) Highly sensitive system and methods for analysis of troponin
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
BRPI0611670A2 (pt) método para o tratamento ou prevenção de câncer em um indivíduo
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2008028968A3 (en) Compounds regulating calreticulin, kdel receptor and/or erp-57 cell surface exposure and uses thereof to evaluate the efficiency of a cancer treatment
WO2005117938A3 (en) Methods of treating ocular conditions
WO2006037462A3 (en) Cancer markers
EP2527466A3 (en) Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008073629A3 (en) Bifunctional predictors of cancer treatment sensitivity and resistance
MX2007005115A (es) Combinacion de un inhibidor de proteina cinasa src y un inhibidor de proteina cinasa bcr-abl para el tratamiento de enfermedades proliferativas.
EP1742654A4 (en) ANTI-LFL2 ANTIBODIES FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER
WO2006110594A3 (en) Sema4d in cancer diagnosis, detection and treatment
WO2008061020A3 (en) Methods of treating, diagnosing or detecting cancer
WO2006116016A3 (en) Molecular determinants of egfr kinase inhibitor response in glioblastoma
MX2013011431A (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.